<?xml version='1.0' encoding='utf-8'?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2011//EN" "http://www.ncbi.nlm.nih.gov/entrez/query/DTD/pubmed_110101.dtd">
<pubmedarticleset>
 <pubmedarticle>
  <medlinecitation owner="NLM" status="MEDLINE">
   <pmid version="1">
    15354280
   </pmid>
   <datecreated>
    <year>
     2004
    </year>
    <month>
     09
    </month>
    <day>
     08
    </day>
   </datecreated>
   <datecompleted>
    <year>
     2004
    </year>
    <month>
     12
    </month>
    <day>
     02
    </day>
   </datecompleted>
   <daterevised>
    <year>
     2010
    </year>
    <month>
     11
    </month>
    <day>
     18
    </day>
   </daterevised>
   <article pubmodel="Print">
    <journal>
     <issn issntype="Print">
      1542-3565
     </issn>
     <journalissue citedmedium="Print">
      <volume>
       2
      </volume>
      <issue>
       9
      </issue>
      <pubdate>
       <year>
        2004
       </year>
       <month>
        Sep
       </month>
      </pubdate>
     </journalissue>
     <title>
      Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
     </title>
     <isoabbreviation>
      Clin. Gastroenterol. Hepatol.
     </isoabbreviation>
    </journal>
    <articletitle>
     Effect of tegaserod in chronic constipation: a randomized, double-blind, controlled trial.
    </articletitle>
    <pagination>
     <medlinepgn>
      796-805
     </medlinepgn>
    </pagination>
    <abstract>
     <abstracttext label="BACKGROUND AND AIMS" nlmcategory="OBJECTIVE">
      Chronic constipation is a common gastrointestinal disorder. The aim of this study was to evaluate the efficacy, safety, and tolerability of tegaserod, a serotonin subtype 4 receptor partial agonist in patients with chronic constipation.
     </abstracttext>
     <abstracttext label="METHODS" nlmcategory="METHODS">
      This was a randomized, double-blind, placebo-controlled study. After a 2-week baseline, patients received tegaserod 2 mg twice daily (n = 450), tegaserod 6 mg twice daily (n = 451), or placebo (n = 447) for 12 weeks, followed by a 4-week withdrawal period. Responders were those patients having been treated for at least 7 days with an increase of &gt; or =1 complete spontaneous bowel movement/week vs. baseline during weeks 1-4 (primary variable) and weeks 1-12 (secondary variable). Other secondary variables included patient assessment of constipation symptoms (number of bowel movements, stool form, abdominal bloating/distention, straining, and abdominal pain/discomfort), and global assessment of constipation and bowel habits.
     </abstracttext>
     <abstracttext label="RESULTS" nlmcategory="RESULTS">
      Responder rates for complete spontaneous bowel movement during weeks 1-4 were significantly greater ( P &lt; 0.0001) in the tegaserod 2 mg twice daily (41.4%) and 6 mg twice daily groups (43.2%) vs. placebo (25.1%). This effect was maintained over 12 weeks. Statistically significant improvements over placebo were observed across the majority of secondary variables for both tegaserod doses. No rebound effect was observed after treatment withdrawal. Tegaserod was well tolerated; headache and nasopharyngitis, the most frequent adverse events, were more common in the placebo group than in either tegaserod group.
     </abstracttext>
     <abstracttext label="CONCLUSIONS" nlmcategory="CONCLUSIONS">
      Over 12 weeks, tegaserod treatment produced significant improvements in chronic constipation symptoms and was also safe and well tolerated.
     </abstracttext>
    </abstract>
    <affiliation>
     University of Illinois College of Medicine, Rockford, IL, USA.
    </affiliation>
    <authorlist completeyn="Y">
     <author validyn="Y">
      <lastname>
       Johanson
      </lastname>
      <forename>
       John F
      </forename>
      <initials>
       JF
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Wald
      </lastname>
      <forename>
       Arnold
      </forename>
      <initials>
       A
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Tougas
      </lastname>
      <forename>
       Gervais
      </forename>
      <initials>
       G
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Chey
      </lastname>
      <forename>
       William D
      </forename>
      <initials>
       WD
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Novick
      </lastname>
      <forename>
       James S
      </forename>
      <initials>
       JS
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Lembo
      </lastname>
      <forename>
       Anthony J
      </forename>
      <initials>
       AJ
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Fordham
      </lastname>
      <forename>
       Fiona
      </forename>
      <initials>
       F
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Guella
      </lastname>
      <forename>
       Mary
      </forename>
      <initials>
       M
      </initials>
     </author>
     <author validyn="Y">
      <lastname>
       Nault
      </lastname>
      <forename>
       Brigitte
      </forename>
      <initials>
       B
      </initials>
     </author>
    </authorlist>
    <language>
     eng
    </language>
    <publicationtypelist>
     <publicationtype>
      Clinical Trial
     </publicationtype>
     <publicationtype>
      Journal Article
     </publicationtype>
     <publicationtype>
      Randomized Controlled Trial
     </publicationtype>
     <publicationtype>
      Research Support, Non-U.S. Gov't
     </publicationtype>
    </publicationtypelist>
   </article>
   <medlinejournalinfo>
    <country>
     United States
    </country>
    <medlineta>
     Clin Gastroenterol Hepatol
    </medlineta>
    <nlmuniqueid>
     101160775
    </nlmuniqueid>
    <issnlinking>
     1542-3565
    </issnlinking>
   </medlinejournalinfo>
   <chemicallist>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Gastrointestinal Agents
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Indoles
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      0
     </registrynumber>
     <nameofsubstance>
      Serotonin Receptor Agonists
     </nameofsubstance>
    </chemical>
    <chemical>
     <registrynumber>
      145158-71-0
     </registrynumber>
     <nameofsubstance>
      tegaserod
     </nameofsubstance>
    </chemical>
   </chemicallist>
   <citationsubset>
    IM
   </citationsubset>
   <meshheadinglist>
    <meshheading>
     <descriptorname majortopicyn="N">
      Chronic Disease
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Constipation
     </descriptorname>
     <qualifiername majortopicyn="Y">
      drug therapy
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Dose-Response Relationship, Drug
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Double-Blind Method
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Gastrointestinal Agents
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="N">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Humans
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Indoles
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Male
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Middle Aged
     </descriptorname>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Serotonin Receptor Agonists
     </descriptorname>
     <qualifiername majortopicyn="N">
      adverse effects
     </qualifiername>
     <qualifiername majortopicyn="Y">
      therapeutic use
     </qualifiername>
    </meshheading>
    <meshheading>
     <descriptorname majortopicyn="N">
      Treatment Outcome
     </descriptorname>
    </meshheading>
   </meshheadinglist>
  </medlinecitation>
  <pubmeddata>
   <history>
    <pubmedpubdate pubstatus="pubmed">
     <year>
      2004
     </year>
     <month>
      9
     </month>
     <day>
      9
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="medline">
     <year>
      2004
     </year>
     <month>
      12
     </month>
     <day>
      16
     </day>
     <hour>
      9
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
    <pubmedpubdate pubstatus="entrez">
     <year>
      2004
     </year>
     <month>
      9
     </month>
     <day>
      9
     </day>
     <hour>
      5
     </hour>
     <minute>
      0
     </minute>
    </pubmedpubdate>
   </history>
   <publicationstatus>
    ppublish
   </publicationstatus>
   <articleidlist>
    <articleid idtype="pubmed">
     15354280
    </articleid>
    <articleid idtype="pii">
     S1542356504003568
    </articleid>
   </articleidlist>
  </pubmeddata>
 </pubmedarticle>
</pubmedarticleset>

